Overview
ENTX market data
Price History
ENTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.91 – $3.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $102.3 · P/B 6.79 · P/S 458.64.
Company news
8-K filing — Entera Bio Ltd. (ENTX)SEC EDGAR · Jul 16, 2026, 8:07 PM
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to MarketGlobenewswire Inc · Jun 23, 2026, 1:15 PM
Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Company's Oral Osteoporosis TabletBenzinga · Jun 23, 2026, 1:01 PM
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat OsteoporosisBenzinga · Jun 22, 2026, 4:35 PM
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical DevelopmentBenzinga · Jun 16, 2026, 12:50 PM
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Reports Phase 1 Data Showing Single-Tablet EB613 Matches Forteo PK/PD ProfileBenzinga · Jun 15, 2026, 12:55 PM
Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16Benzinga · May 28, 2026, 1:00 PM